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Scolopendra extracts were used for pharmacopuncture at the Kidney 1 acupoint to
investigate the role of Scolopendra pharmacopuncture (SPP) in both the development
and maintenance of neuropathic pain induced by L5 spinal nerve ligation in rats and
the contribution of spinal glial cells. A single treatment and five once-daily treatments
with SPP were given to evaluate its effects on the development and maintenance
stages of neuropathic pain, respectively, which was followed by behavioral tests.
Immunohistochemistry and Western blotting tests were also carried out. A single treat-
ment of SPP delayed spinal nerve ligation-induced mechanical allodynia and thermal
hyperalgesia and induced a profound decrease in the expression of ionized calcium
binding adaptor protein in the lumbar spinal cord. Repeated SPP treatments reliably
suppressed mechanical allodynia and thermal hyperalgesia at later time points, and
these results correlated mainly with decreases in glial fibrillary acidic protein. Intrigu-
ingly, ionized calcium binding adaptor protein expression was also reduced after
repeated SPP. These results illustrate that neuropathic pain in the development andf Meridian and Structural Medicine, School of Korean Medicine, Pusan National University,
angsan Gyeongnam 626-870, Republic of Korea.
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Analgesic Effects of Scolopendra Pharmacopuncture 237maintenance stages is alleviated by SPP treatment, which may be ascribed principally
to deactivations of microglia and astroglia, respectively. Additionally, microglial inac-
tivation seems to be partially involved in preventing neuropathic pain in the mainte-
nance stage.1. Introduction
Peripheral nerve injury is frequently accompanied by
neuropathic pain, which is characterized by spontaneous
burning pain, hyperalgesia, and allodynia [1e3]. Intensive
research has led to major progress in the understanding of
the basic mechanisms of the development and the main-
tenance of neuropathic pain. Convincing evidence indicates
that the activations of spinal microglia and astrocytes, as
evaluated by overexpression of glial activation markers
such ionized calcium binding adaptor protein (Iba-1) and
glial fibrillary acidic protein (GFAP), are observable
following L5 spinal nerve ligation (SNL) [4e7]. However,
neuropathic pain is often poorly managed when treated by
using currently available medications owing to the presence
of many side effects, including motor dysfunction, seda-
tion, and tolerance [8e12]. Thus, the issue of neuropathic
pain has recently become more visible and has been
recognized as one of the most intractable challenges to
modern medicine [13,14].
Alternatively, acupuncture has been traditionally uti-
lized to treat peripheral neuropathy in Korean medicine
[15e18]. Laboratory studies have demonstrated that elec-
troacupuncture alleviates neuropathic pain via suppression
of the activation of spinal glial cells [19]. Furthermore, the
acupoint Kidney 1 (KI1) has been shown to be involved in
alleviating diabetic peripheral neuropathy, contributing to
treatment with alliance combination of electroacupuncture
and acupoint injection [20]. More recently, pharmaco-
puncture with the herbal drug Sciatica 5, which is emerging
as a promising treatment, has been reported to facilitate
functional recovery after peripheral nerve injury [21]. The
centipede Scolopendra subspinipes mutilans L. Koch has a
reputation in traditional East Asian medicine for being
effective in treating a variety of disorders, such as joint
problems, tetanus, stroke, convulsions, neoplasm, Alz-
heimer’s disease, and so forth [22,23]. In addition, water
extracts of Scolopendra have analgesic properties, as evi-
denced by the increased pain threshold in mice during hot-
plate tests [24].
As many ideas are based more on speculation than on
fact, the question as to whether injection of Scolopendra
extracts into KI1 is capable of suppressing the allodynic and
the hyperalgesic responses to mechanical and thermal
stimuli comparable to the peripheral neuropathic condition
induced by using L5 SNL [25], the signs of which closely
resemble certain clinical symptoms of human patients with
causalgia and reflex sympathetic dystrophy [26], is still
appropriate. If the answer is yes, then deciphering whether
the analgesic effect of Scolopendra pharmacopuncture
(SPP) is correlated with the suppression of the activation of
spinal glial cells in the initiation and maintenance of
neuropathic pain would make more sense.2. Materials and methods
2.1. SPP and control group treatment protocols
A pharmacopuncture recipe for Scolopendra extract was
obtained from the Korean Pharmacopuncture Institute
(Seoul, Korea). Pharmacopuncture therapy was performed
at the KI1 acupoint, which is located at the depression in
the middle of the metatarsal area on the plantar side of the
back, using a 1 mL disposable insulin injection syringe with
a 29-gauge needle to slowly inject 200 mL of Scolopendra
extract (1 mg). The depth of needle insertion was about
5e15 mm. When the needle was inserted into the skin, a
sharp and painful sensation was induced, and a spreading,
lumpish sensation around the injection site was reported.
With regard to a control intervention, because Scolopendra
extract and normal saline (SAL) are identical in appear-
ance, normal saline was utilized, instead of Scolopendra
extract, to stimulate the acupoint identically. As additional
controls, the selected acupoint, the needle used, the depth
of needle penetration, the dose injected, and the treat-
ment schedule were identical throughout this research.
2.2. Animals
Experiments were performed on young adult male Spra-
gueeDawley rats (200e250 g; Hyochang Science, Daegu,
Korea). The rats were randomly allocated to five groups as
follows: Group A (naı¨ve, n Z 3); Group B (1 time injection
of SAL at Day 0, SNL þ SAL, n Z 8); Group C (1 time in-
jection of SPP at Day 0, SNL þ SPP, n Z 8); Group D
(repeated injection of SAL, SNL þ SAL, nZ 8); and Group E
(repeated injection of SPP, SNL þ SPP, n Z 8). All rats
underwent behavioral tests, as well as immunohistochem-
istry and Western blot analysis. During the experimental
period, all animals were housed in groups of three in plastic
cages with soft bedding and a 12/12-hour reversed lighte
dark cycle in a temperature (22e25C)-controlled environ-
ment with ad libitum access to food and water. All exper-
imental procedures were carried out in accordance with
the Animals (Scientific Procedures) Act 2008 (Korea) and
complied with the recommendations of the National Insti-
tute of Health’s Guide for the Care and Use of Laboratory
Animals. The study was approved by the Ethics Committee
on Animal Research at Pusan National University, Yangsan
Gyeongnam, Korea (PNU-2012-0090).
2.3. Neuropathic surgery
Rats were anesthetized with isoflurane (3% induction, 2%
maintenance) in a mixture of N2O/O2, and a midline skin
incision was made on the back at the lower lumbar region.
238 C. Li et al.The paraspinal muscles were retracted, and the right
transverse process of the L6 vertebra was removed under a
dissection microscope. Then, the right L5 spinal nerve was
identified and tightly ligated, as described in a previous
report [25].
2.4. Evaluation of neuropathic pain sensitivity
Mechanical allodynia was assessed by using a dynamic
plantar anesthesiometer (Ugo Basile, Varese, Italy) to
measure the threshold to withdraw the hind paw from a
graded force applied to the paw’s surface with a Von Frey
filament. The cutoff force was set at 50 g. Thermal
hyperalgesia was assessed by using a commercial plantar
test apparatus (Ugo Basile) to measure the latency to
withdraw the hind paw from a focused beam of radiant heat
(infrared intensity was 70) applied to the plantar surface
(Hargreave’s method). The cut-off latency was set at 30
seconds.
2.5. Immunohistochemistry
The L5e6 segments of the spinal cords were dissected by
performing a laminectomy on the 4th day and the 11th day
after SNL and were fixed in 4% paraformaldehyde for 6e8
hours, after which they were immersed in 30% sucrose for
48 hours at 4C. Frozen tissues were sectioned at a thick-
ness of 30 mm on a freezing microtome (CM3050S; Leica
Biosystems, Wetzlar, Germany). The tissue sections were
processed for immunostaining using the Avidin-Biotin
Complex method (Vector Laboratories, Burlingame, CA,
USA). In more detail, the sections were washed with 0.05M
phosphate-buffered saline (PBS) and incubated in 3%
hydrogen peroxide for 10 minutes. After rinses, the sections
were blocked with CAS-block (Invitrogen-Molecular Probes,
Inc., Camorillo, CA, USA) for 10 minutes at room temper-
ature, followed by incubation overnight in PBS at 4C with
primary antibodies: mouse anti-GFAP (1:400, #MAB360;
Millipore, Temecula, CA, USA) and mouse anti-Iba-1 (1:200,
#ab15691; Abcam, Cambridge, UK). Sections were sequen-
tially rinsed with PBS containing Tween-20 (PBST), followed
by incubation with the biotinylated secondary antibody
goat anti-mouse (1:100, #BA9200; Vector Laboratories) for
2 hours at room temperature. Several rats per group were
chosen, and approximately five nonoverlapping optical
sections were randomly selected for each rat and utilized
to quantify GFAP or Iba-1 positive glial cells.
2.6. Western blot analysis
The ipsilateral half of the L5-6 segments of the spinal cords
on the nerve-ligated side was excised on the 4th day and the
11th day after SNL. Equal amounts of protein lysate were
separated by 8e12% sodium dodecyl sulfa-
teepolyacrylamide gel electrophoresis, after which the
resolved proteins were transferred to nitrocellulose mem-
branes (GE Healthcare, Little Chalfont, Buckinghamshire,
UK). Primary antibodies used were mouse anti-GFAP
(1:1000, #MAB360; Millipore), rabbit anti-Iba-1 (1:250,
#ab48004; Abcam), and rabbit anti-actin (1:200, #A2066;
Sigma-Aldrich, St Louis, MO, USA). Horseradish peroxidase-conjugated secondary antibodies used were goat anti-
mouse (1:2,000, #sc2005; Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA, USA) and goat anti-rabbit (1:5,000,
#sc2004; Santa Cruz Biotechnology, Inc.). The membrane
reacted to the enhanced chemiluminescent substrate
(#34087; Thermo Fisher Scientific Inc., Rockford, IL, USA)
and was analyzed using a luminescent image analyzer
(ImageQuant LAS 4000; GE Healthcare).
Quantification of the immunoreactivity was performed by
using a densitometric analysis with Image J version 1.47v
(Wayne Rasband, National Institutes of Health, USA). Each
representative band selected was calculated three times,
and the relative densitometry unit of Iba-1 or GFAP expres-
sion normalized to internal actin expression was employed.
2.7. Statistical analyses
All values are presented as mean  standard error of the
mean. The paired t-test was used to determine whether
significant differences in behavioral scores between prior to
and after SNL were present, and a one-way repeated
measure analysis of variance (ANOVA), followed by Bon-
ferroni’s t-test, was utilized to examine whether significant
differences in behavioral scores between prior to and after
SPP treatment emerged. Moreover, the two-sample t-test
was performed between the naı¨ve and the SAL þ SNL
groups, as well as between the SAL- and the SPP-treated
groups. All statistical analyses were carried out using Sig-
maStat version 11.0 (Systat Software, San Jose, CA, USA). A
p value < 0.05 was considered statistically significant.
3. Results
To evaluate the effect of SPP on early stage neuropathic
pain, a single injection of SPP (1 mg/200 mL) or SAL (200 mL)
was administered immediately after SNL, followed by
assessment of mechanical allodynia on postoperative Day
(POD) 0, POD 1, POD 3, and POD 5 and assessment of
thermal hyperalgesia on POD 0, POD 2, POD 4, and POD 6,
respectively, in both the SNLþSAL (nZ 7) and the SNLþSPP
(n Z 7) groups. As revealed by the behavioral results pre-
sented in Fig. 1, SPP treatment delayed mechanical allo-
dynia and thermal hyperalgesia. The two sample t-test
showed a statistically significant difference between the
SNL rats administered SAL and SPP (p < 0.05, n Z 7 rats/
group), which further elucidates that SPP treatment pro-
duces relief of early-phase neuropathic pain.
As shown in Fig. 2A, a profound decrease of Iba-1 posi-
tive cells in SPP-treated SNL rats in comparison with SAL-
treated ones, was confirmed, which was analyzed quanti-
tatively as described in Fig. 2B, where a statistically sig-
nificant reduction by 50.75% was revealed for one
treatment with SPP (p < 0.05, t-test). In addition, one
treatment with SPP resulted in diminished translational
levels of Iba-1, which was also monitored using Western
blot analysis (Fig. 2C). In Fig. 2D, which presents data for
the levels of Iba-1 normalized to internal actin (Iba-1/actin)
as measured by using a densitometric analysis and
expressed as standardized ratios, a statistically significant
reduction by 59.4% was identified for one treatment with
SPP (p < 0.001, t-test). Strikingly, an analogous tendency
Figure 1 Delayed (A) mechanical allodynia and (B) thermal hyperalgesia induced by spinal nerve ligation in rats treated with
Scolopendra pharmacopuncture only once postoperatively. )p < 0.05 vs. spinal nerve ligation þ saline group. Arrows indicate
saline or Scolopendra pharmacopuncture injection time points.
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astrocytes by using immunohistochemical analyses
(Fig. 3A and B). However, the decrease in the number of
activated astrocytes by 27.3% for one SPP treatmentFigure 2 Downregulated ionized calcium binding adaptor prote
receiving one shot of Scolopendra pharmacopuncture (SPP) immed
istry photomicrographs of the L5 spinal dorsal horn in SNL rats adm
antibody recognizing Iba-1. Images (aec) and (def) were viewed
200 mm for (aec) and 100 mm for (def). (B) Bar graph presenting the
vs. naı¨ve group; )p < 0.05, SNLþSPP vs. SNLþSAL group), n Z 3. (
undergoing different treatments, as obtained using western blotti
(Iba-1/actin) of the SNLþSPP group to those of the SNLþSAL group (
marker.exhibited no statistically significant difference in compari-
son with SAL-administered SNL rats (p > 0.05, t-test;
Fig. 3A and B), which was supported by the unchanged GFAP
protein levels seen in the Western blot analysis (Fig. 3C andin (Iba-1) on postoperative Day 4 in the spinal cords of rats
iately after spinal nerve ligation (SNL). (A) Immunohistochem-
inistered one shot of saline (SAL) and SPP and incubated with
by using a 10  and a 20  lens, respectively. Scale bars are
number of Iba-1 positive microglia cells (##p < 0.001, SNLþSAL
C) Protein levels of Iba-1 and actin in the L5 spinal cord of rats
ng. (D) Standardized ratio of the relative integrated densities
))p < 0.001 vs. SNLþSAL group), nZ 3. Iba-1 is the microglial
Figure 3 Unchanged glial fibrillary acidic protein (GFAP) on postoperative Day 4 in the spinal cords of rats receiving one shot of
Scolopendra pharmacopuncture (SPP) immediately after spinal nerve ligation (SNL). (A) Immunohistochemistry photomicrographs
of the L5 spinal dorsal horn in SNL rates administered one shot of saline (SAL) and SPP and incubated with antibody recognizing
GFAP. Images (aec) and (def) were viewed by using a 10  and a 20  lens, respectively. Scale bars are 200 mm for (aec) and
100 mm for (def). (B) Bar graph presenting the number of GFAP positive astrocytes [#p < 0.05, SNLþSAL vs. naı¨ve group; naı¨ve
(nZ 3), SNLþSAL (nZ 5), SNLþSPP (nZ 5)]. (C) Protein levels of GFAP and actin in the L5 spinal cords of rats undergoing different
treatments, as obtained using Western blotting. (D) Standardized ratio of the relative integrated densities (GFAP/actin) of the
SNLþSPP group to those of the SNLþSAL group, n Z 3. GFAP is the astrocytic marker.
240 C. Li et al.D). The emerging evidence leads us to speculate that the
alleviated development of neuropathic pain after one SPP
treatment seems to be attributed to the attenuation of
microglial activation.
To assess the effect of SPP on late-stage neuropathic
pain, we initiated five once-daily treatments with SPP
(1 mg/200 mL) or SAL (200 mL) from Day 3 after SNL, when
neuropathic pain had already developed. The mechanical
allodynia and thermal hyperalgesia assessments of the
SNL þ SAL (n Z 6) and the SNL þ SPP (n Z 7) groups that
were done prior to surgery were compared with those done
daily from POD 3 to POD 11 following SNL. As shown in
Fig. 4A and B, in both the SAL- and the SPP-injected rats,
SNL resulted in a significant decline in the threshold and the
latency of hind-paw withdrawal on Day 3 after surgery,
which represented both mechanical allodynia and thermal
hyperalgesia [p < 0.05, p < 0.001 vs. presurgical baselines
(POD 0), paired t-test]. Moreover, the paw-withdrawal
threshold (PODs 8e11) and the paw-withdrawal latency
on POD 5 and PODs 9e11 due to five treatments with SPP
were distinguishable from those of the SAL-treated rats
[p < 0.05, p < 0.001 vs. SNL þ SPP (POD 3); Fig. 4A and B].
The one-way repeated measures ANOVA followed by Bon-
ferroni’s post hoc test showed a statistically significantdifference between the SAL- and the SPP-treated SNL rats
on some PODs (p < 0.05, p < 0.001 vs. SNLþSAL group, t-
test; Fig. 4A and B). These data further support the notion
that repeated SPP treatment inhibits the maintenance of
neuropathic pain.
Figs. 5A and 6A show marked increases in Iba-1 and GFAP
positive cells of rats that underwent SNL as compared to
naı¨ve rats, as well as dramatic decreases in those, of SPP-
treated SNL rats as compared with SAL-treated ones.
These results are analyzed quantitatively in the accompa-
nying graphs (Figs. 5B and 6B), where statistically signifi-
cant increases in the numbers of Iba-1 and GFAP positive
glial cells by 83.6% and 341.2% due to SNL, respectively
(p < 0.001 SNLþSAL vs. naı¨ve group, t-test). In addition,
reductions in the numbers of those cells by 22.4% and 25.5%
after repeated SPP treatment, respectively, were observed
(p < 0.05 SNLþSPP vs. SNLþSAL group, t-test).
Moreover, exposure to repeated SPP treatment led to
decreased GFAP protein levels, which were monitored using
Western blot analysis (Fig. 6C). In Fig. 6D, where the levels
of GFAP normalized to internal actin (GFAP/actin) were
measured by using a densitometric analysis and expressed
as a standardized ratio, shows a very significant reduction
by 30.92% after repeated SPP treatment (p < 0.05, t-test).
Figure 4 Attenuated late-phase neuropathic pain behaviors induced by spinal nerve ligation (SNL) in rats treated repetitively by
using postligation with Scolopendra pharmacopuncture (SPP). SNL resulted in significant reductions in the hind-paw-withdrawal
threshold and the latency to mechanical and thermal stimuli, respectively, compared to those prior to saline (SAL) or SPP was
administered [þp < 0.05, þþp < 0.001 vs. the presurgical value (postoperative Day 0)]. Repeated daily injections of SPP suppressed
SNL-induced (A) mechanical allodynia and (B) thermal hyperalgesia at late times in neuropathic rats ()p < 0.05, ))p < 0.001 vs.
SNLþSPP group (postoperative Day 3). The difference between the SNLþSPP and the SNLþSAL groups was statistically significant
(#p < 0.05, ##p < 0.001 vs. SNLþSAL group). Arrows indicate SAL or SPP injection time points.
Figure 5 Downregulated ionized calcium binding adaptor protein (Iba-1) on postoperative Day 11 in the spinal cords of rats
receiving repeated Scolopendra pharmacopuncture (SPP) after spinal nerve ligation (SNL). (A) Immunohistochemistry photomicro-
graphs of the L5 spinal dorsal horn in SNL rats repeatedly administered saline (SAL) and SPP and incubated with antibody recognizing
Iba-1. Images (aec) and (def) were viewed by using a 10 and a 20 lens, respectively. Scale bars are 200 mmfor (aec) and 100 mmfor
(def). (B) Bar graph presenting the number of Iba-1 positivemicroglia cells [##p< 0.001, SNLþSAL vs. naı¨ve group;)p< 0.05, SNLþSPP
vs. SNLþSAL group; naı¨ve (nZ 3), SNLþSAL (nZ 5), SNLþSPP (nZ 5)]. (C) Protein levels of GFAP and actin in the L5 spinal cord of
rats undergoing different treatments, as obtained using western blotting. (D) Standardized ratio of the relative integrated densities
(Iba-1/actin) of the SNLþSPP group to those of the SNLþSAL group, nZ 3. Iba-1 is the microglial marker.
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Figure 6 Downregulated glial fibrillary acidic protein (GFAP) on postoperative Day 11 in the spinal cord of rats receiving repeated
Scolopendra pharmacopuncture (SPP) after spinal nerve ligation (SNL). (A) Immunohistochemistry photomicrographs of the L5
spinal dorsal horn in SNL rats repeatedly administered saline (SAL)and SPP and incubated with antibody recognizing GFAP. Images
(aec) and (def) were viewed by using a 10  and a 20  lens, respectively. Scale bars are 200 mm for (aec) and 100 mm for (def).
(B) Bar graph presenting the number of GFAP positive astrocytes [##p < 0.001, SNLþSAL vs. the naı¨ve group; )p < 0.05, SNLþSPP vs.
SNLþSAL group; naı¨ve (nZ 3), SNLþSAL (n Z 5), SNLþSPP (nZ 5)]. (C) Protein levels of GFAP and actin in the L5 spinal cords of
rats undergoing different treatments, as obtained using western blotting. (D) Standardized ratio of the relative integrated densities
(GFAP/actin) of the SNLþSPP group to those of the SNLþSAL group ()p < 0.05 vs. SNL þ SNL group), nZ 3. GFAP is the astrocytic
marker.
242 C. Li et al.However, the phenotype was not reduced in the Iba-1
protein levels presented in Fig. 5C and D. Current data in-
crease the plausibility that suppression of microglial and
astrocytic activations participates in the suppressive po-
tential of repeated SPP treatment for managing neuro-
pathic pain during its maintenance phase.4. Discussion
As observed, a single post-SNL treatment with SPP induced
suppression of mechanical allodynia and thermal hyper-
algesia paralleling microglial deactivation on POD 4. How-
ever, although microglial activation had fallen to near the
basal level for naı¨ve rats as the result of SPP treatment,
intriguingly, the symptoms of neuropathic pain did not
decrease to the degrees seen in naı¨ve rats or to the pre-
baseline levels. Two concerns have been raised. Activated
satellite glial cells have been well documented to play a
role in the early maintenance (PODs 3e7) of allodynia after
SNL [27]. In addition, the role of Schwann cells in neuro-
pathic pain have gradually received close attention in thelatest study [21], although few researchers have investi-
gated the contributions of SPP treatment to the separate
phases of neuropathic pain. The assertion that other cell
phenotypes, just like satellite or Schwann glial cells, will
play additional roles in the early phase neuropathic pain,
on which SPP treatment has no beneficial effect, seems
plausible. Another possible interpretation is that spinal Iba-
1 upregulation after SNL, which is shown in our data, may
be associated with nerve injury, but may not be a cause of
neuropathic pain. This is supported by the results that,
although SNL-induced phosphorylation of c-Jun in spinal
astroglia, the peptide JNK inhibitor D-JNKI-1, can block
neuropathic pain, it is not accompanied by a reduction of
GFAP expression [5]. Therefore, the method using changes
in the expressions of spinal glial cells markers as indicators
of the magnitude of pain remains controversial. It is the
changes in the signaling molecules, not the structural pro-
teins, in spinal glial cells, that are important for pain
sensitization. Therefore, two highly interesting perspec-
tives are opened: the upstream one in which spinal glial
cells are activated and the downstream one in which
products are released by activated glial cells.
Analgesic Effects of Scolopendra Pharmacopuncture 243In addition, we found that the SNL rats that were treated
only once with SPP did not return to the post-baseline of
the saline-treated rats in POD 6, which indicates the long-
term analgesic potential of SPP. However, a long longitu-
dinal study will be needed. The results present an experi-
mental paradigm for investigating the advantages of early
clinical intervention, through which chronic neuropathic
pain processes will be better prevented.
As predicted, SNL produced stable mechanical allodynia
and thermal hyperalgesia, which was in agreement with
previous studies [5,7,25,27]. After the neuropathic pain had
been established, we performed SPP treatment on Days
3e7 when microglial and astrocytic cells should be at high
levels in the L5/6 dorsal horn. This treatment attenuated
mechanical allodynia from Day 6 to Day 11. By contrast, the
treatment only partly suppressed thermal hyperalgesia on
POD 5 and PODs 9e11, but the suppression was greater
after the final treatment, suggesting a cumulative effect of
SPP treatment.
In parallel with the behavioral results, repeated SPP
treatments reduced both microglial and astrocytic activa-
tions, as indicated by the immunohistochemistry analysis.
However, a discrepancy existed between the results of the
immunohistochemistry and the Western blot analyses. Even
though similar trends were observable, only the reductions
in the GFAP protein levels showed statistical differences in
Western blot results, which suggested that the deactivation
of astrocytes mainly contributed to the maintenance of
neuropathic pain. To some extent, microglial deactivation
may be involved in the attenuated mechanical allodynia
and thermal hyperalgesia in the early maintenance phase
(PODs 5e7) of neuropathic pain.
Among the various pharmacopuncture formulae, this
study used Scolopendra pharmacopuncture because the
extracts or ingredients of Scolopendra have been purified
or identified, such as a serine protease [28], peptide SQL
(Ser-Gln-Leu) [29], and centipede acidic protein [30] and
have been reported to improve the hemorrheological
disturbances, polysaccharide level (which has specific
effects on tumor cells [31]), and the levels of two quin-
oline alkaloids (3,8-dihydroxyquinoline and 2,8-dihydroxy-
3,4-dimethoxyguinoline) and 2,4-di-tertbutylphenol
(which have antioxidant effects) [32]. In addition, several
lines of evidence have indicated that extracts of Scolo-
pendra might effectively relieve the pain associated with
joint injury by increasing expressions of IL-2, IL-4, and IL-
10 [33], might suppress the growth of cervical tumors by
regulating Bax- and Caspase-3-medicated mitochondrial
signal transit pathways [34], and might have antisenility
effects by decreasing the contents of lipid peroxide in the
serum and of lipofuscin in the liver and brain tissues of
rats [35]. The extracts also play a protective role during
the development of cerulean-induced acute pancreatitis
and acute pancreatitis-associated lung injury by deacti-
vating c-Jun NH2-terminal kinase, p38 and nuclear factor
kB, thereby inhibiting the release of high-mobility group
box protein-1 and proinflammatory cytokine [36].
Furthermore, the ingredient centipede acidic protein,
isolated from Scolopendra, has anti-atherogenic effects
through the inhibition of lipid peroxidation and the
regulation of the nitric oxide and the endothelin-1 sys-
tems [30].Recent in vitro and in vivo assays have reported Scolo-
pendra to have a positive effect for treating many disor-
ders, but no evidence of its effect on neuropathic pain has
been reported. Furthermore, as reported previously [37],
scolopendrid waterealcohol extract applied to the ipsilat-
eral BL23 acupoint produced a more significant improve-
ment of neuropathic pain sensitivity than its application to
the contralateral BL23, ST25, or LR3 acupoint did, which
demonstrates the specific effect of the acupoint used for
the treatment. Based on these considerations, we thought
that extracts from Scolopendra might have constituents
contributing to the suppression of neuropathic pain. Thus,
in this study, Scolopendra extract was used to manufacture
pharmacopuncture for injections on KI1 and was tested for
its efficacy in neuropathic rats. As predicted, the main ef-
fect of SPP is thought to be the interaction between the
action of the KI1 acupoint and the injected medicine,
Scolopendra extract.
In summary, the inhibitory effects of SPP on the devel-
opment and maintenance of neuropathic pain may be
associated with the deactivations of microglia and astro-
glia, respectively. Additionally, microglia inactivation
seems to be, at least in part, responsible for the effects of
SPP in preventing neuropathic pain during the maintenance
phase. The potential application of SPP in separate phases
of neuropathic pain is implied by the results of this study;
hence, future works are expected to shed light on identi-
fying which constituents in Scolopendra extracts are
effective for the management of neuropathic pain and to
lead to the development of direct and exact therapeutic
strategies for the management of such pain.
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